



Alkoxyphenylthiazoles with broad-spectrum activity against multi-drug resistant gram-positive pathogens.

Thesis
submitted by
Moustafa ElAwamy Mohamed (BSc.)

Bachelor Degree of Pharmaceutical Sciences,
Faculty of Pharmacy, MSA University (2013).

In Partial Fulfillment of the Requirements of the
Master Degree
In Pharmaceutical Sciences.
“Pharmaceutical Chemistry”.

Under supervision of

Prof. Dr. Khaled Abouzid Mohamed
Professor of Pharmaceutical Chemistry,
Faculty of Pharmacy, Ain Shams University and
Dean of the faculty of Pharmacy, University of Sadat City.

Dr. Rabah Ahmed Taha
Associate Professor of Pharmaceutical Chemistry
and Deputy Head of the Pharmaceutical Chemistry Department
Faculty of Pharmacy, Ain Shams University

Dr. Abdelrhman Salah Mayhoub
Associate Professor of Organic Chemistry
Faculty of Pharmacy, Al Azhar University

Ain-Shams University
Cairo- Egypt
2019

ACKNOWLEDGEMENTS

In the name of **Allah**, the Most Gracious and the Most Merciful.

Alhamdulillah, all praises to Allah for the strengths and His blessing in completing my thesis finally, after all the challenges and difficulties.

Foremost, I would like to express my special appreciation and thanks to my advisor **Prof. Dr.**

Khaled Abouzid, Professor of Pharmaceutical Chemistry and Dean of Faculty of Pharmacy, University of Sadat City, for his guidance and support throughout this study. Prof. Khaled is someone you will instantly love and never forget once you meet him. Words cannot express how grateful I am to his kindness, immense knowledge, scientific advices and many insightful discussions and suggestions. I could not have imagined having a better advisor and mentor for my master's study.

I would also like to give special thanks to **Assoc. Prof. Dr. Rabah Ahmed Taha**, Assoc. Prof. and Acting Head of the Pharmaceutical Chemistry Department, Ain Shams University, for allowing me to conduct this research under her auspices. Her time, careful attention to details and advice on both research as well as on my career have been invaluable.

In particular, I would like to sincerely thank the initiator of this work **Assoc. Prof. Dr. Abdelrhman S. Mayhoub**, Associate Professor of Pharmaceutical Organic Chemistry, Al Azhar University, for his heartfelt support, indispensable guidance, inspiration and suggestions in my quest for knowledge. He provided me an opportunity to join his team "Mayhoub Lab" and gave me a full access to his laboratory and research facilities. Without his precious support, it would not be possible to conduct this research by any means. Honestly, I consider Dr. Abdelrhman like an elder brother, a friend, a role model and a pillar of support.

I owe a debt of gratitude to **Professor Dr. Azza Taher**, Professor of Organic Chemistry and Head of the Organic Chemistry Department, October 6 University, for the patient guidance, encouragement and advice she has provided throughout my research. Prof. Azza is such a captivating, honest, and a true embodiment of a mentor. I have been extremely lucky to have a supervisor who cared so much about my work, and who responded to my queries promptly.

A special mention for **Dr. Mohamed Hagra**s, Lecturer of Organic Chemistry, Al Azhar University, for the sleepless nights and being instrumental in helping me crank out this thesis. Dr. Hagra is sophisticated person but also practical and down to earth. I gratefully acknowledge his unwavering support and guidance.

I also thank my fellow labmates **Dr. Mohamed Al Sebaay**, Hany Gamal, M. Hanoun, A. Mostafa, for generously sharing their expertise and for their helpful suggestions whenever I had problems during the study.

I'd also like to extend my gratitude to **Mohamed Adel** for his forensic scrutiny of my technical writing and has always found the time to propose consistently excellent improvements.

Not forgotten, I should also appreciate my lab partner Abdelrhman M. Hussin, for helping me throughout the synthesis journey.

DEDICATION

My acknowledgement would be incomplete without thanking the biggest source of my strength, my family. Without the endless love, great efforts and unceasing prayers of my parents, I would have never had the courage to overcome the adversities I have faced, and to you both, I dedicat this thesis. The love and care of my brothers; Ahmed, Ali and Yousif and particularly my prime source of ideas, Mahmoud and his beloved son, Moaaz, who never let things get dull or boring. And of course, my sweet heart sister and nephews, have all made a tremendous contribution in helping me reach this stage in my life. Thank you all for putting up with me in difficult moments where I felt stumped and for goading me on to follow my dream of getting this degree. This would not have been possible without your unwavering and unselfish love and support at all times.

Finally, I would like to take this opportunity to thank all my friends and colleagues who have given their support and help especially my best buddies, Islam, Fathallah and Hazem.

If I did not mention someone's name here, it does not mean that I do not acknowledge your support and help. Again, I would like to thank everyone who supported and helped me during my master's study.

Thank you all...

Besides the work presented in this thesis, the candidate successfully passed the Master's general and special postgraduate courses in Pharmaceutical Chemistry in the academic year 2017/2018 with the following grades;

1) Comprehensive Organic Chemistry	A ⁻
2) Computer Aided Drug Design	B ⁻
3) Methods of Drug Screening	A ⁻
4) Structure Elucidation of Chemical Entities	B ⁺
5) Pharmaceutical Chemistry	B ⁻
6) Stereochemistry	C
7) Biostatistics	C ⁺
8) Scientific Writing and Research Ethics	C ⁺
9) Instrumental Analysis	B
10) Bioinformatics	C

TABLE OF CONTENTS

Acknowledgements	I
Dedication	III
Table of contents.....	V
List of Figures	VIII
List of Abbreviations	XI
1. Introduction	1
1.1. Overview	1
1.2. Brief history of antibiotics and their modes of action.....	2
1.2.1. Dawn of the modern era	2
1.2.2. Penicillin.....	3
1.2.3. The Golden Age	6
1.3. Antibiotic resistance.....	14
1.4. Causes of the antibiotic resistance.....	16
1.4.1. Overuse	16
1.4.2. Inappropriate Prescribing.....	17
1.4.3. Extensive use in the Animal Husbandry and Agriculture.....	18
1.4.4. Availability of Few New Antibiotics.....	19

1.4.5.	Regulatory Barriers	21
1.5.	Mechanisms of antibiotic resistance	22
1.5.1.	Genetic basis of antimicrobial resistance	23
1.5.2.	Mechanistic basis of antimicrobial resistance.....	26
1.6.	Gram-positive resistance	37
1.6.1.	Methicillin and Vancomycin Resistant <i>S. aureus</i>	38
1.6.2.	Methicillin-Resistant <i>Staphylococcus epidermidis</i>	39
1.6.3.	vancomycin-resistant enterococci.....	40
1.6.4.	Cephalosporin-resistant and methicillin-resistant <i>Streptococcus pneumoniae</i>	40
1.6.5.	<i>Listeria monocytogenes</i>	41
1.7.	Strategies to minimize antibiotic resistance	41
1.7.1.	Preventative solutions.....	42
1.7.2.	Remedial Measures.....	44
1.8.	Phenylthiazoles as a Novel Class against multi-drug resistant bacteria ...	45
1.9.	In vivo proof-of-principle	48
1.10.	Pharmacokinetic profiling.....	50
2.	Rationale and design.....	52
2.1.	optimization of the old generations	52
2.2.	Innovation and research design.....	55

2.3.	Thesis goals	57
3.	Results and discussion.....	58
3.1.	Chemistry	58
3.2.	Biological results and discussion	Error! Bookmark not defined.
4.	Conclusion	75
5.	Experimental part.....	77
5.1.	Materials and instrumentation.....	77
5.2.	Synthesis.....	78
5.3.	Microbiological Assays	100
5.3.1.	Determination of MIC and MBC against Gram-positive bacterial pathogens	100
5.3.2.	Time-kill assay against MRSA	100
5.3.3.	Resistance study against MRSA.....	101
5.3.4.	In vitro cytotoxicity analysis against Caco-2 cells	101
5.3.5.	In vivo pharmacokinetics	102
6.	References	103

LIST OF FIGURES

Figure 1 Deaths attributable to AMR every year by 2050.....	16
Figure 2 Novel FDA approved antibacterial and non-bacterial drugs by year (last 15 years). ...	20
Figure 3 An overview of intrinsic resistance mechanisms.....	24
Figure 4 Mechanisms of horizontal gene transfer (HGT).	26
Figure 5 Reactions catalyzed by AACs.	28
Figure 6 General mechanism of Ser-h-lactamases and metallo-h-lactamases.	30
Figure 7 Different types of efflux pumps in gram-positive and gram-negative bacteria.	33
Figure 8 Change in antibiotic target sites	34
Figure 9 Time killing assay of lead compound 1a, vancomycin and teicoplanin.	45
Figure 10 Previous modification at the lipophilic moiety.	46
Figure 11 The effect of vancomycin and oxacillin to re-sensitize VRSA.....	47
Figure 12 Efficacy of treatment with 6 doses of topical phenylthiazole (2%) in MRSA infected BALB/c mice (n=5).	49
Figure 13 Progression of healing and infection of inoculated wounds on days 0 (inoculation), 3, 7, 12.....	49
Figure 14 MIC values & Pharmacokinetic profile of lead Structure.	50
Figure 15 Major detected metabolites of lead compound 1a in blood and urine.....	53
Figure 16 Overcoming the metabolic instability of the old generation phenylthiazoles.....	53
Figure 17 Optimization of the old generation of phenylthiazole antibiotics.....	55
Figure 18 Developmental progress of phenylthiazole antibiotics and the new approach to extend the antibacterial activity.	56

Figure 19 Time-kill analysis of compounds 16a, 17a, and vancomycin against MRSA	70
Figure 20 Multi-step resistance selection of compounds 16A, 17A, and rifampicin against methicillin-resistant <i>S. aureus</i> USA400 (NRS123).....	72
Figure 21 Toxicity analysis of alkoxyphenylthiazoles against human colorectal cells.....	73

LIST OF TABLES

Table 1. The minimum inhibitory concentration (MIC in µg/mL) of compounds initially screened against methicillin-resistant <i>Staphylococcus aureus</i> (2658 RCMB).	67
Table 2. The minimum inhibitory concentration (MIC in µg/mL) and minimum bactericidal concentration (MBC in µg/mL) of tested compounds <i>Staphylococcus aureus</i> clinical isolates. ..	68
Table 3. The minimum inhibitory concentration (MIC in µg/mL) and minimum bactericidal concentration (MBC in µg/mL) of tested compounds against Gram-positive bacterial pathogens including <i>Staphylococcus epidermidis</i> , <i>Enterococcus faecalis</i> , <i>E. faecium</i> , <i>Listeria monocytogenes</i> , and <i>Streptococcus pneumoniae</i>	69
Table 4. In vivo PK parameters of compound 17a in rat after single IV bolus injection.	74

LIST OF ABBREVIATIONS

AACs	Aminoglycoside acetyltransferases
ABC	ATP-binding cassette family
AIDS	Acquired immune deficiency syndrome
AMEs	Aminoglycoside modifying enzymes
AMR	Antimicrobial resistance
AST	Antimicrobial susceptibility testing
CDC	Center for disease prevention and control
CFR	Chloramphenicol–florfenicol resistance
CFUs	Colony forming units
CIMS	Chemical ionization mass spectrometry
CDC	Centre for disease control and prevention
DCM	Dichloromethane
DHFR	Dihydrofolate reductase
DMF	Dimethylformamide
DMF-DMA	Dimethylformamide-dimethyl acetal
EARSS	European antimicrobial resistance surveillance system
ECDC	European center for disease prevention and control
ERM	Erythromycin ribosome methylase
ESIMS	Electrospray ionization mass spectroscopy
FIC	Factory inhibitory concentration
GAIN	Generating antibiotic incentives now
HaCaT	Human keratinocytes
HGT	Horizontal gene transfer
HRMS	High resolution mass spectroscopy
HTS	High throughput screening
IC ₅₀	Sample concentration which causes 50% inhibition
ICUs	Intensive care units
IMS	Intercontinental marketing services
IDSA	Infectious disease society of America

LPAD	Limited-population antibiotic drug
LR	Lawesson's reagent
MATE	Multidrug and toxic compound extrusion family
MCPBA	<i>m</i> -chloroperbenzoic acid
MDR	Multidrug resistant
MDRP	Multidrug-resistant pathogens
MeOH	Methanol
MGEs	Mobile genetic elements
MIC	Minimum inhibitory concentration
MRSA	Methicillin-resistant <i>Staphylococcus aureus</i>
MRSE	Methicillin-resistant <i>Staphylococcus epidermidis</i>
MSSA	Methicillin sensitive <i>Staphylococcus aureus</i>
MFS	Major facilitator superfamily
NAPCAB	National action plan for combating antibiotic-resistant bacteria
NIH	National institutes of health
NPV	Net present value
PBP	Penicillin-binding protein
POC	Point-of-care
RDTs	Rapid diagnostic tests
RND	Resistance-nodulation-cell-division family
SMR	Small multidrug resistance family
SSTIs	Skin and soft-tissue infections
TMP-SMX	Trimethoprim-Sulfamethoxazole
UppP	Undecaprenyl pyrophosphate phosphatase
UppS	Undecaprenyl pyrophosphate synthase
VISA	Vancomycin-intermediate <i>Staphylococcus aureus</i>
VRE	Vancomycin-resistant enterococci
VRSA	Vancomycin-resistant <i>Staphylococcus aureus</i>

Abstract:

Title of thesis:

**“Alkoxyphenylthiazoles with broad-spectrum activity against
multidrug-resistant gram-positive bacterial pathogens”**

Name of candidate:

Moustafa ElAwamy Mohamed (BSc.)

Bachelor Degree of Pharmaceutical Sciences,
Faculty of Pharmacy, MSA University, 2013.

Thesis supervised by:

Prof. Dr. Khaled Abouzid Mohamed

*Professor of Pharmaceutical Chemistry,
Faculty of Pharmacy, Ain Shams University*

Dr. Rabah Ahmed Taha

*Associate Professor of Pharmaceutical Chemistry
and Deputy Head of the Pharmaceutical Chemistry Department
Faculty of Pharmacy, Ain Shams University*

Dr. Abdelrhman Salah Mayhoub

*Associate Professor of Organic Chemistry
Faculty of Pharmacy, Al Azhar University*

With the continued rise of antibiotic resistance and reduced susceptibility to almost all front-line antibiotics, multidrug-resistant Gram-positive bacterial infections represent an incessant threat to healthcare providers. Antibiotic resistance kills an estimated 700,000 people each year worldwide, and some experts predict that number to reach 10 million by 2050 if efforts are not made to curtail resistance or develop new antibiotics. Although the development of second- and third antibacterial generations from the existing classes of antibiotics has improved the overall activity, bacterial resistance to these known drugs is on an exponential rise.

Previously, phenylthiazoles have been identified as a new scaffold with a notable efficacy against highly multidrug-resistant Gram-positive pathogens by using HTS on a wide variety of methicillin and vancomycin-resistant *Staphylococcus aureus* strains. Unfortunately, the promising activity of this novel class of antibiotics was hampered by their short half-life due to rapid hepatic metabolism. The lead compound **1a**, as a representative example, was cleared by liver microsomes at a rate of 80.3 $\mu\text{L}/\text{min}\cdot\text{mg}$.

According to SAR analysis, Phenylthiazole scaffold has to carry two important structural features: basic guanidine moiety and lipophilic tail. Starting from the lead compound **1a**, a ligand-based drug design approach has been adopted in order to improve the antibacterial potency of the lead structure. A second generation phenylthiazole derivatives have been developed by replacing the rapidly hydrolysable Schiff-base moiety of the lead compound **1a** with cyclic unhydrolyzable bioisosteres; i.e. pyrimidine ring. And a series of 5-pyrimidophenylthiazoles with different moieties at position-5 has been synthesized and evaluated. As well as the incorporation of different cyclic bioisosteres instead of the *n*-butyl at the *p*-position of the phenyl group.

Later, metabolite profiling study determined the benzylic carbon of the lead compound **1a** as an easily metabolized soft spot. Rapidly metabolized and cleared in human liver microsomes resulting in a very short half-life (<30 min). Upon replacement this particular methylene with an oxygen atom, the biological life span increased by more than eight-fold while maintaining their potent anti-MRSA activity.